Related Experiment Video

Updated: Nov 10, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.8K

Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination

Ioannis A Vathiotis1, Jennifer M Johnson2, Athanassios Argiris2

  • 1Department of Pathology, Yale University, 310 Cedar Street, New Haven, CT, USA.

Cancer Treatment Reviews
|April 5, 2021
PubMed

Insights

Anti-programmed cell death protein 1 (PD-1) immunotherapy shows promise for head and neck squamous cell carcinoma (HNSCC). This review explores emerging immunotherapy combinations to improve treatment efficacy in HNSCC patients.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Anti-programmed cell death protein 1 (PD-1) immunotherapy is a standard treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
  • The efficacy of PD-1 inhibitors is limited to a subset of patients, necessitating combination strategies.
  • Head and neck squamous cell carcinoma (HNSCC) exhibits a highly immunosuppressive tumor microenvironment.

Purpose of the Study:

  • To review current clinical and preclinical data on immunotherapy combinations for HNSCC treatment.
  • To identify emerging targets and strategies for combination immunotherapy in HNSCC.
  • To provide insights into novel therapeutic approaches for HNSCC.

Main Methods:

  • Literature review of clinical trials and preclinical studies.
  • Synthesis of emerging data on immunotherapy combinations in HNSCC.
  • Analysis of immune regulatory pathways in HNSCC.

Main Results:

  • Preliminary results from clinical trials evaluating immunotherapy combinations are emerging.
  • Preclinical evidence is accumulating for novel targets in combination immunotherapy.
  • Understanding the interplay of immune pathways is crucial for HNSCC treatment.

Conclusions:

  • Combination immunotherapy holds significant potential for improving HNSCC treatment outcomes.
  • Further research into novel targets and combinations is warranted.
  • Targeting the immunosuppressive HNSCC microenvironment is key to enhancing immunotherapy efficacy.
Keywords:
HNSCCImmunotherapyPD-1PD-L1

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

958
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
816
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K